Compounds > n-glycolylneuraminyllactosylceramide
Page last updated: 2024-08-04 06:51:32
n-glycolylneuraminyllactosylceramide
Description
N-glycolylneuraminyllactosylceramide: influenza A virus receptor which mediates the adsorption-fusion process of viral infection [MeSH]
N-glycolylneuraminyllactosylceramide : A sialotriaosylceramide in which the triaosyl group is 3,5-dideoxy-5-(2-hydroxyacetamido)-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl attached to the primary hydroxy function of ceramide. A tumour antigen found in solid tumors such as breast carcinoma, nonsmall cell lung cancer, and melanoma, but not usually detected in normal human cells. [CHeBI]
Cross-References
Synonyms (14)
| Synonym |
|---|
| CHEBI:144806 |
| hd3 ganglioside |
| neugc-gm3 |
| 69345-49-9 |
| n-glycolyl-neuraminyl-lactosyl-ceramide |
| n-glycolylneuraminyllactosylceramide |
| (2s,3r,4e)-3-hydroxy-2-(octadecanoylamino)octadec-4-en-1-yl 3,5-dideoxy-5-(2-hydroxyacetamido)-d-glycero-alpha-d-galacto-non-2-ulopyranonosyl-(2->3)-beta-d-galactopyranosyl-(1->4)-beta-d-glucopyranoside |
| neugc(alpha2-3)gal(beta1-4)glc(beta1-1)cer |
| n-glycoloyl-gm3 |
| gm3-neugc |
| ceramide, 1-o-(o-(n-(hydroxyacetyl)-alpha-neuraminosyl)-(2-3)-o-beta-d-galactopyranosyl-(1-4)-beta-d-glucopyranosyl)- |
| ganglioside gm3, n-deacetyl-n-(hydroxyacetyl)-, (5alpha,17alpha)- |
| HD3 , |
| (2s,4s,5r,6r)-2-[(2s,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e,2s,3r)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1r,2r)-1, |
Roles (1)
| Role | Description |
|---|
| tumour antigen | An antigenic substance produced in tumour cells, which triggers an immune response in the host. |
Drug Classes (1)
| Class | Description |
|---|
| sialotriaosylceramide | A ganglioside in which the oligosaccharide portion is composed of a trisaccharide, to which one or more sialic acid residues are attached. |
Research
Studies (39)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 8 (20.51) | 18.2507 |
| 2000's | 10 (25.64) | 29.6817 |
| 2010's | 18 (46.15) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 5 (11.90%) | 5.53% |
| Reviews | 7 (16.67%) | 6.00% |
| Case Studies | 1 (2.38%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 29 (69.05%) | 84.16% |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Abnormalities, Autosome | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Animal Mammary Carcinoma | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Argentaffinoma | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Benign Neoplasms | 0 | | 1991 | 2014 | 16.3 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| Breast Cancer | 0 | | 1991 | 2017 | 22.2 | low | 2 | 0 | 3 | 1 | 1 | 0 |
| Breast Neoplasms | 0 | | 1991 | 2017 | 22.2 | low | 2 | 0 | 3 | 1 | 1 | 0 |
| Bronchial Neoplasms | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Colon | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cancer of Esophagus | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cancer of Eye | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Lung | 0 | | 2008 | 2018 | 10.5 | low | 1 | 0 | 0 | 1 | 5 | 0 |
| Cancer of Mouth | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Ovary | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Pancreas | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cancer of Stomach | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cancer of the Retina | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carcinoid Tumor | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carcinoma, Lewis Lung | 0 | | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Carcinoma, Non-Small Cell Lung | 0 | | 2008 | 2018 | 10.3 | low | 1 | 0 | 0 | 1 | 6 | 0 |
| Carcinoma, Non-Small-Cell Lung | 0 | | 2008 | 2018 | 10.3 | low | 1 | 0 | 0 | 1 | 6 | 0 |
| Cholelithiasis | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cirrhosis, Liver | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Colonic Neoplasms | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Dermatoses | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Disease Exacerbation | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disease Models, Animal | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| E coli Infections | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Escherichia coli Infections | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Esophageal Neoplasms | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Extravascular Hemolysis | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Eye Cancer, Retinoblastoma | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Gallstone Disease | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Germinoblastoma | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hemolysis | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Intestinal Diseases | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Kahler Disease | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leukemia L 1210 | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Liver Cirrhosis | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Local Neoplasm Recurrence | 0 | | 2012 | 2019 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Lung Neoplasms | 0 | | 2008 | 2018 | 10.5 | low | 1 | 0 | 0 | 1 | 5 | 0 |
| Lymphoma | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Malignant Melanoma | 0 | | 1985 | 2012 | 25.0 | low | 1 | 1 | 2 | 1 | 1 | 0 |
| Melanoma | 0 | | 1985 | 2012 | 25.0 | low | 1 | 1 | 2 | 1 | 1 | 0 |
| Metastase | 0 | | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Mouth Neoplasms | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple Myeloma | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Necrosis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neoplasm Metastasis | 0 | | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Neoplasms | 0 | | 1991 | 2014 | 16.3 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| Neoplasms, Bronchial | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neuroectodermal Tumors | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nevi, Melanocytic | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nevus, Pigmented | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ovarian Neoplasms | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pancreatic Neoplasms | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Plasma Cell Tumor | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Plasmacytoma | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Recrudescence | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Retinoblastoma | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sarcoma | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sarcoma, Epithelioid | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Skin Diseases | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Stomach Neoplasms | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Vitiligo | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 40, Issue:8, 2017
Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-15, Volume: 21, Issue:6, 2003
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.Hybridoma, , Volume: 19, Issue:3, 2000
Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.Hybridoma, , Volume: 17, Issue:6, 1998
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 29, Issue:2
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.Cancer immunology, immunotherapy : CII, , Volume: 67, Issue:8, 2018
Racotumomab for treating lung cancer and pediatric refractory malignancies.Expert opinion on biological therapy, , Volume: 16, Issue:4, 2016
Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.Expert review of vaccines, , Volume: 14, Issue:1, 2015
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 20, Issue:14, 2014
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.Journal of immunology (Baltimore, Md. : 1950), , Nov-01, Volume: 181, Issue:9, 2008
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.Cancer immunology, immunotherapy : CII, , Volume: 67, Issue:8, 2018
Racotumomab for treating lung cancer and pediatric refractory malignancies.Expert opinion on biological therapy, , Volume: 16, Issue:4, 2016
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 20, Issue:14, 2014
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.Journal of immunology (Baltimore, Md. : 1950), , Nov-01, Volume: 181, Issue:9, 2008
N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.Oral diseases, , Volume: 18, Issue:8, 2012
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study.Cancer biology & therapy, , Volume: 7, Issue:4, 2008
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.Hybridoma, , Volume: 19, Issue:3, 2000
[Induction of anti-melanoma CTL by GM3 (NeuGc)-liposomes].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 48, Issue:2, 1990
Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma.The Journal of biological chemistry, , Oct-25, Volume: 260, Issue:24, 1985
Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.BMC cancer, , Jun-10, Volume: 19, Issue:1, 2019
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.Clinical & experimental metastasis, , Volume: 33, Issue:7, 2016
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 29, Issue:2
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties.European journal of immunology, , Volume: 43, Issue:3, 2013
Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.Clinical and experimental immunology, , Volume: 167, Issue:2, 2012
NGcGM3 ganglioside: a privileged target for cancer vaccines.Clinical & developmental immunology, , Volume: 2010, 2010
Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells.Cancer immunology, immunotherapy : CII, , Volume: 55, Issue:4, 2006
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.Clinical & experimental metastasis, , Volume: 33, Issue:7, 2016
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 40, Issue:8, 2017
Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-15, Volume: 21, Issue:6, 2003
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.Hybridoma, , Volume: 19, Issue:3, 2000
Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.Hybridoma, , Volume: 17, Issue:6, 1998
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 29, Issue:2
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.Cancer immunology, immunotherapy : CII, , Volume: 67, Issue:8, 2018
Racotumomab for treating lung cancer and pediatric refractory malignancies.Expert opinion on biological therapy, , Volume: 16, Issue:4, 2016
Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.Expert review of vaccines, , Volume: 14, Issue:1, 2015
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 20, Issue:14, 2014
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.Journal of immunology (Baltimore, Md. : 1950), , Nov-01, Volume: 181, Issue:9, 2008
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.Cancer immunology, immunotherapy : CII, , Volume: 67, Issue:8, 2018
Racotumomab for treating lung cancer and pediatric refractory malignancies.Expert opinion on biological therapy, , Volume: 16, Issue:4, 2016
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 20, Issue:14, 2014
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.Journal of immunology (Baltimore, Md. : 1950), , Nov-01, Volume: 181, Issue:9, 2008
N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.Oral diseases, , Volume: 18, Issue:8, 2012
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study.Cancer biology & therapy, , Volume: 7, Issue:4, 2008
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.Hybridoma, , Volume: 19, Issue:3, 2000
[Induction of anti-melanoma CTL by GM3 (NeuGc)-liposomes].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 48, Issue:2, 1990
Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma.The Journal of biological chemistry, , Oct-25, Volume: 260, Issue:24, 1985
Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.BMC cancer, , Jun-10, Volume: 19, Issue:1, 2019
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.Clinical & experimental metastasis, , Volume: 33, Issue:7, 2016
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 29, Issue:2
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties.European journal of immunology, , Volume: 43, Issue:3, 2013
Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.Clinical and experimental immunology, , Volume: 167, Issue:2, 2012
NGcGM3 ganglioside: a privileged target for cancer vaccines.Clinical & developmental immunology, , Volume: 2010, 2010
Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells.Cancer immunology, immunotherapy : CII, , Volume: 55, Issue:4, 2006
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Safety/Toxicity (1)